2023
CyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post‐Treatment Hearing Status
Hildrew D, Perez P, Mady L, Li J, Nilsen M, Hirsch B. CyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post‐Treatment Hearing Status. The Laryngoscope 2023, 134: s1-s12. PMID: 37178050, DOI: 10.1002/lary.30731.Peer-Reviewed Original ResearchConceptsTumor control rateCyberKnife stereotactic radiosurgeryHearing outcomesVestibular schwannomaControl rateStereotactic radiosurgeryRetrospective case series reviewCase series reviewThird of patientsProportional hazard modelingMaximum radiation doseSeries reviewTumor controlAvailable audiogramsOtolaryngology-HeadTumor volumeEffective treatmentClass APatientsHearing statusAmerican AcademyHazard modelingVolumetric analysisRadiation doseOutcomes
2021
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.
Ahmed K, Kim Y, Arrington J, Kim S, DeJesus M, Soyano A, Armaghani A, Costa R, Khong H, Rosa M, Caudell J, Diaz R, Robinson T, Etame A, Tran N, Sahebjam S, Soliman H, Forsyth P, Yu H, Han H. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study. Journal Of Clinical Oncology 2021, 39: e14010-e14010. DOI: 10.1200/jco.2021.39.15_suppl.e14010.Peer-Reviewed Original ResearchBreast cancer brain metastasesCancer brain metastasesProgression-free survivalBrain metastasesStereotactic radiosurgeryBrain metastasis controlStudy therapyControl rateMetastasis controlCertain breast cancer patientsNeuro-Oncology Brain MetastasesSystemic progression-free survivalDose of nivolumabNeurologic adverse eventsImmune checkpoint inhibitionPhase Ib studyPhase Ib trialSolid Tumors criteriaResponse Evaluation CriteriaKey eligibility criteriaTumor control rateFeasible treatment optionBreast cancer patientsBrain metastasis managementExtracranial disease
2014
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.Peer-Reviewed Original ResearchClinical complete responseOropharyngeal squamous carcinomaLate grade 3 toxicityPost-treatment neck dissectionStage III/IVAHigh tumor control ratesGrade 3 toxicityWeek x 3Tumor control rateHuman papilloma virusLate toxicityPrimary endpointCurrent smokersComplete responseNeck dissectionNodal stageSquamous carcinomaControl ratePapilloma virusC-IMRTT1-3Weekly schedulePFSInvolved nodesDose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply